Indian Institute of Technology (IIT) Mandi researchers have recognized a drug molecule that can be utilized to deal with diabetes. The molecule is known as as PK2 and is ready to set off the discharge of insulin by the pancreas and may probably be used as an orally administered medication for diabetes.
The findings of the analysis have been revealed within the Journal of Biological Chemistry. The paper has been authored by Prosenjit Mondal, affiliate professor, School of Basic Sciences, and co-authored by Subrata Ghosh, professor, School of Basic Sciences, IIT Mandi, together with Sunil Kumar, ICAR- IASRI, PUSA, New Delhi, Budheswar Dehury, ICMR RMRC, Bhubaneswar, Khyati Girdhar, Shilpa Thakur, Abhinav Choubey, Pankaj Gaur, Surbhi Dogra, Bidisha Biswas from IIT Mandi, and Durgesh Kumar Dwivedi (Regional Ayurvedic Research Institute (RARI) Gwalior)
“Current drugs such as exenatide and liraglutide used for diabetes, are administered as injections, and they are costly and unstable after administration. We seek to find simpler drugs that are stable, cheap, and effective against both Type 1 and Type 2 diabetes,” Mondal stated.
“We first tested the binding of PK2 on GLP1R proteins in human cells and found that it is able to bind well toGLP1R proteins. This showed that PK2 can potentially trigger insulin release by the beta cells,” Girdhar stated.
According to the researchers, PK2 was quickly absorbed by the gastrointestinal tract, which implies that it may be used as an oral medicine slightly than an injection. “Beyond increasing insulin release, PK2 was also able to prevent and even reverse beta cell loss, a cell essential for insulin production, making it effective for both Type 1 and Type 2 diabetes,” Mondal added.
Read Also: UP Madarsa Education Board decides Urdu, Arabic, Persian and ‘Diniyat’ to be taught taught as one topic
Source: www.financialexpress.com”